

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Alcon launches Hydrus Microstent for long-term glaucoma management in India

10 March 2026 | News

Hydrus Microstent is available in the US, Canada, Australia, Japan, and select European and APAC countries



Alcon, the global leader in eye care, has announced the launch of Hydrus® Microstent in India. This minimally invasive glaucoma surgery (MIGS) device is designed to lower intraocular pressure (IOP) for patients with open-angle glaucoma in conjunction with cataract surgery.

MIGS are a lower risk intervention for glaucoma patients, enabling physicians to lower IOP with a reduced risk of complications compared to incisional filtration surgeries while allowing for rapid visual recovery. Hydrus' HORIZON trial is the first and only MIGS study to report 5-year clinical outcomes, with continuous follow up and 80% patient retention at year five.

Hydrus is also recognised by leading medical bodies and evidence reviews including the European Glaucoma Society (EGS), Cochrane, and the American Academy of Ophthalmology (AAO) for the quality of its data. With over 200,000 implants worldwide, Hydrus Microstent is a proven solution for sustained IOP control.

"In India, approximately 12 million people are affected by glaucoma, and the proportion of undiagnosed glaucoma is estimated at around 90%, underscoring the need for earlier detection and effective interventional treatment options^{2,3}. At Alcon, we're committed to bringing Hydrus to India to help glaucoma patients continue to see brilliantly. Hydrus' unique Tri-Modal® mechanism of action enables its clinical effectiveness, and our high-quality, long-term data give surgeons the confidence to manage glaucoma both safely and effectively. This launch marks a significant milestone for the ophthalmic community and the many patients it serves," said Amar Vyas, Country Head at Alcon India.